372 related articles for article (PubMed ID: 27548441)
1. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
Brizzi MP; Pignataro D; Tampellini M; Scagliotti GV; Di Maio M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1053-62. PubMed ID: 27548441
[TBL] [Abstract][Full Text] [Related]
2. Novel drugs in clinical development for hepatocellular carcinoma.
Waidmann O; Trojan J
Expert Opin Investig Drugs; 2015; 24(8):1075-82. PubMed ID: 26108356
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
Hollebecque A; Malka D; Ferté C; Ducreux M; Boige V
Eur J Cancer; 2015 Feb; 51(3):327-39. PubMed ID: 25559615
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Rimassa L; Pressiani T; Personeni N; Santoro A
Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
[TBL] [Abstract][Full Text] [Related]
5. Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach.
Villanueva A
J Hepatol; 2013 Aug; 59(2):392-5. PubMed ID: 23548196
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.
Lee SJ; Lim HY
Expert Opin Emerg Drugs; 2017 Jun; 22(2):191-200. PubMed ID: 28506080
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib: from literature to clinical practice.
Di Marco V; De Vita F; Koskinas J; Semela D; Toniutto P; Verslype C
Ann Oncol; 2013 Apr; 24 Suppl 2():ii30-7. PubMed ID: 23715941
[TBL] [Abstract][Full Text] [Related]
9. Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
Tovoli F; Lorenzo S; Barbera MA; Garajova I; Frega G; Palloni A; Pantaleo MA; Biasco G; Brandi G
Future Oncol; 2017 Sep; 13(21):1893-1905. PubMed ID: 28693355
[TBL] [Abstract][Full Text] [Related]
10. Pathways and targets in hepatocellular carcinoma.
Psyrri A; Arkadopoulos N; Vassilakopoulou M; Smyrniotis V; Dimitriadis G
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1347-57. PubMed ID: 23176622
[TBL] [Abstract][Full Text] [Related]
11. Oral chemotherapy for the treatment of hepatocellular carcinoma.
Yamamoto S; Kondo S
Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
13. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
14. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.
Llovet JM; Hernandez-Gea V
Clin Cancer Res; 2014 Apr; 20(8):2072-9. PubMed ID: 24589894
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.
Germano D; Tinessa V; Barletta E; Cannella L; Daniele B
Drugs Aging; 2013 Nov; 30(11):887-92. PubMed ID: 24097332
[TBL] [Abstract][Full Text] [Related]
17. New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
Woo HY; Yoo SY; Heo J
Expert Opin Pharmacother; 2017 Jan; 18(1):35-44. PubMed ID: 27849399
[TBL] [Abstract][Full Text] [Related]
18. Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding?
Dekervel J; van Pelt J; Verslype C
Curr Opin Oncol; 2013 Jul; 25(4):409-16. PubMed ID: 23680714
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Gnoni A; Santini D; Scartozzi M; Russo A; Licchetta A; Palmieri V; Lupo L; Faloppi L; Palasciano G; Memeo V; Angarano G; Brunetti O; Guarini A; Pisconti S; Lorusso V; Silvestris N
Expert Opin Ther Targets; 2015; 19(12):1623-35. PubMed ID: 26212068
[TBL] [Abstract][Full Text] [Related]
20. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]